Vertex Pharmaceuticals Publishes Presentation on Kidney Disease Research

By Public Technologies
  • Vertex Pharmaceuticals published its “Vertex 2026 Final ASN Presentation,” outlining kidney drug trial results and development milestones.
  • Povetacicept reduced proteinuria by 52% at Week 36 in the Phase 3 RAINIER interim analysis; the placebo-adjusted reduction was 49.8%.
  • Serious adverse events occurred in 3% of povetacicept recipients versus 4.3% with placebo.
  • A November 30 PDUFA target date is set for povetacicept in IgA nephropathy.
  • Inaxaplin’s pivotal AMPLITUDE trial is fully enrolled, with interim analysis data expected in early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.